IGI Logo

Glenmark Pharmaceuticals is currently trading at Rs. 483.05, up by 3.85 points or 0.80% from its previous closing of Rs. 479.20 on the BSE.

The scrip opened at Rs. 483.80 and has touched a high and low of Rs. 485.20 and Rs. 478.05 respectively. So far 11706 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 690.60 on 19-Jul-2021 and a 52 week low of Rs. 415.60 on 07-Mar-2022.

Last one week high and low of the scrip stood at Rs. 485.20 and Rs. 450.50 respectively. The current market cap of the company is Rs. 13521.50 crore.

The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 35.04% and 18.31% respectively.

Glenmark Pharmaceuticals’ subsidiary -- Glenmark Specialty S.A. (Glenmark) has received approval from the Indian drug regulator, Drug Controller General of India (DCGI), to conduct a Phase 1 clinical trial of its novel small molecule, GRC 54276, a hematopoietic progenitor kinase 1 (HPK1) inhibitor.

HPK1 is a key regulator of T cell, B cell and dendritic cell-mediated immune responses, which improves antitumor immunity by activating and priming T cells. GRC 54276 has shown tumor cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology.

The study will evaluate the safety and tolerability of GRC 54276 as a monotherapy, and also in combination with checkpoint inhibitors in patients with advanced solid tumors and Hodgkin’s lymphoma. Glenmark will initiate Phase 1 clinical trial in India by June 2022, and also plans to file an IND in the US and Clinical Trial Applications in Europe to kick-off a fully global clinical study program.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.